Company intelligence / Profile preview

EDC BioSynergy

Chuncheon, Gangwon-do, South Koreabiosynergy.co.kr ↗

Ownership: Private
Development stage: Other

Overview

BioSynergy is a South Korean biotechnology company focused on the development of functional food ingredients and therapeutic agents derived from natural sources. The company specializes in metabolic diseases, particularly targeting type 2 diabetes and obesity through the modulation of PPAR receptors. BioSynergy leverages its expertise in natural product chemistry to identify and validate bioactive compounds for use in both the nutraceutical and pharmaceutical industries. Their research pipeline includes several candidates aimed at improving insulin sensitivity and lipid metabolism.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small moleculeNatural products
Industry: Biotech

Beyond the preview

Go deeper on EDC BioSynergy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDC BioSynergy.

Explore the full profile